IP Library › Granted Patent US 12,454,544
Granted Patent B2
US 12,454,544 · App. 18/660,815 · Granted Oct 28, 2025

CD73 inhibitors

Inventors: Xiaohui Du (Belmont, CA); John Eksterowicz (Burlingame, CA); Valeria R. Fantin (Burlingame, CA); Daqing Sun (Foster City, CA); Qiuping Ye (Foster City, CA); Jared Moore (San Rafael, CA); Tatiana Zavorotinskaya (Moraga, CA); Brian R. Blank (Daly City, CA); Yosup Rew (Foster City, CA); Kejia Wu (South San Francisco, CA); Liusheng Zhu (Foster City, CA); Johnny Pham (San Bruno, CA); Hiroyuki Kawai (Pacifica, CA); Chien-Hung Yeh (San Bruno, CA)
Assignee: ORIC PHARMACEUTICALS, INC.
C07H19/23A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,454,544
App. No.
18/660,815
Granted
Oct 28, 2025
Kind
B2
Abstract

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Claims (13)

1. A compound having the structure

2. A method of preparing a compound having the structure

comprising reacting a compound having the structure

with 5-(bromomethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-tetrazole in an aprotic solvent and in the presence of a base.

3. The method of claim 2 , wherein the aprotic solvent is N,N-dimethylformamide.

4. The method of claim 2 , wherein the base is sodium hydride.

5. The method of claim 3 , wherein the aprotic solvent is N,N-dimethylformamide and the base is sodium hydride.

6. A method of preparing a compound having the structure

comprising reacting a compound having the structure

bromotrimethylsilane in an aprotic solvent and in the presence of a base.

7. The method of claim 6 , wherein the aprotic solvent is acetonitrile.

8. The method of claim 6 , wherein the base is triethylamine.

9. The method of claim 6 , wherein the aprotic solvent is acetonitrile and the base is triethylamine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2024
From: DU, XIAOHUI; EKSTEROWICZ, JOHN; FANTIN, VALERIA R.; SUN, DAQING; YE, QIUPING; MOORE, JARED; ZAVOROTINSKAYA, TATIANA; BLANK, BRIAN R.; REW, YOSUP; WU, KEIJA; ZHU, LIUSHENG; PHAM, JOHNNY; KAWAI, HIROYUKI; YEH, CHIEN-HUNG
To: ORIC PHARMACEUTICALS, INC.
Reel/Frame 067388/0901 →
Continuity (6)
Continuation 18051125 · Oct 31, 2022
Division 17083871 · Oct 29, 2020
Provisional Application 63088646 · Oct 7, 2020
Provisional Application 62987806 · Mar 10, 2020
Provisional Application 62928138 · Oct 30, 2019
Related Publication 20250034198A1 · Jan 30, 2025
References Cited (89)
US 10239912B2 · Debien et al. · 2019 [cited by applicant]
US 11028120B2 · Du et al. · 2021 [cited by applicant]
US 11129841B2 · Du et al. · 2021 [cited by applicant]
US 11130778B2 · Du et al. · 2021 [cited by applicant]
US 11325938B2 · Du et al. · 2022 [cited by applicant]
US 11377469B2 · Du et al. · 2022 [cited by applicant]
US 11530236B2 · Du et al. · 2022 [cited by applicant]
US 11576922B2 · Du et al. · 2023 [cited by applicant]
US 11807658B2 · Du et al. · 2023 [cited by applicant]
US 12018043B2 · Du · 2024 [cited by examiner]
US 20040229839A1 · Babu et al. · 2004 [cited by applicant]
US 20040266723A1 · Otto et al. · 2004 [cited by applicant]
US 20090029949A1 · Parrill-Baker et al. · 2009 [cited by applicant]
US 20090274686A1 · Or et al. · 2009 [cited by applicant]
US 20170044203A1 · Cacatian et al. · 2017 [cited by applicant]
US 20180072742A1 · Chen et al. · 2018 [cited by applicant]
US 20190309010A1 · Debien et al. · 2019 [cited by applicant]
US 20200093844A1 · Du et al. · 2020 [cited by applicant]
US 20200347090A1 · Du et al. · 2020 [cited by applicant]
US 20210047359A1 · Du et al. · 2021 [cited by applicant]
US 20210130389A1 · Du et al. · 2021 [cited by applicant]
US 20210130390A1 · Du et al. · 2021 [cited by applicant]
US 20210214387A1 · Du et al. · 2021 [cited by applicant]
US 20220054512A1 · Du et al. · 2022 [cited by applicant]
US 20220259253A1 · Du et al. · 2022 [cited by applicant]
US 20220331343A1 · Du et al. · 2022 [cited by applicant]
US 20220411459A1 · Du et al. · 2022 [cited by applicant]
US 20230131747A1 · Du et al. · 2023 [cited by applicant]
US 20240124512A1 · Du et al. · 2024 [cited by applicant]
CN 104530166B · 2016 [cited by applicant]
EP 0477454A1 · 1992 [cited by applicant]
EP 0479640A2 · 1992 [cited by applicant]
JP H04316589A · 1992 [cited by applicant]
WO WO2005020885A2 · 2005 [cited by applicant]
WO WO2008083949A2 · 2008 [cited by applicant]
WO WO2009127230A1 · 2009 [cited by applicant]
WO WO2015164573A1 · 2015 [cited by applicant]
WO WO2017098421A1 · 2017 [cited by applicant]
WO WO2017120508A1 · 2017 [cited by applicant]
WO WO2018049145A1 · 2018 [cited by applicant]
WO WO2018067424A1 · 2018 [cited by applicant]
WO WO2018094148A1 · 2018 [cited by applicant]
WO WO2018119284A1 · 2018 [cited by applicant]
WO WO2018183635A1 · 2018 [cited by applicant]
WO WO2018208727A1 · 2018 [cited by applicant]
WO WO2018208980A1 · 2018 [cited by applicant]
WO WO2019090111A1 · 2019 [cited by applicant]
WO WO2019129059A1 · 2019 [cited by applicant]
WO WO2019213174A1 · 2019 [cited by applicant]
WO WO2019232319A1 · 2019 [cited by applicant]
WO WO2019246403A1 · 2019 [cited by applicant]
WO WO2020046813A1 · 2020 [cited by applicant]
WO WO2020257429A1 · 2020 [cited by applicant]
WO WO2021011689A1 · 2021 [cited by applicant]
WO WO2021087136A1 · 2021 [cited by applicant]
U.S. Appl. No. 17/722,513 Office Action dated Jun. 10, 2024. [cited by applicant]
U.S. Appl. No. 18/476,763 Office Action dated Aug. 12, 2024. [cited by applicant]
Boothroyd, et al. Why Do Some Molecules Form Hydrates or Solvates?. Crystal Growth and Design 18:1903-1908 (2018). [cited by applicant]
Caiazzo et al. The Ecto-5′-Nucleotidase/CD73 Inhibitor, α, β-Methylene Adenosine 5′-Diphosphate, Exacerbates Carrageenan-Induced Pleurisy in Rat. Frontiers in Pharmacology 10:775 (2019). [cited by applicant]
Chan et al. Poster #LB-115. An Orally Bioavailable Inhibitor of CD73 Reverts Intratumoral Immunosuppression and Promotes Anti-Tumor Response. AACR Virtual Annual Meeting II, Jun. 22-24, 2020. [cited by applicant]
Database Accession No. 2018:1846166 (Oct. 4, 2018). [cited by applicant]
Du. Abstract #1242. Orally Bioavailable Small Molecule CD73 Inhibitor Reverses Immunosuppression by Reduction of Adenosine Production. PowerPoint Presentation AACR Annual Meeting Apr. 20, 2020. [cited by applicant]
Du et al. Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production. J Med Chem 63(18):10433-10459 (2020). [cited by applicant]
Ghalamfarsa et al., CD73 as a potential opportunity for cancer immunotherapy. Expert Opinion on Therapeutic Targets 23(2):127-142 (2019). [cited by applicant]
Gillerman et al., 2-Hexylthio-β,γ-CH2-ATP is an effective and selective NTPDase2 inhibitor. J Med Chem. 57(14):5919-34 (2014). [cited by applicant]
Jeffrey et al. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. J Med Chem 63(22):13444-13465 (2020). [cited by applicant]
Metzger et al. Intratumoral Immunosuppression is Reversed by Blocking Adenosine Production with an Oral Inhibitor of CD73. AACR-NCI-EORTC Oct. 27, 2019 Boston, MA. [cited by applicant]
Morisette, et al. High-throughput Crystallization: Polymorphs, Salts, Co-crystals and Solvates of Pharmaceutical Solids. Advanced Drug Delivery Reviews 56(3):275-300 (2004). [cited by applicant]
Nguyen et al. Chiral drugs an overview. Int J Biomed Sci 2(2):85-100 (2006). [cited by applicant]
PCT/US2018/031891 International Search Report and Written Opinion dated Aug. 24, 2018. [cited by applicant]
PCT/US2018/059004 International Search Report and Written Opinion dated Feb. 26, 2019. [cited by applicant]
PCT/US2019/030068 International Search Report and Written Opinion dated Aug. 16, 2019. [cited by applicant]
PCT/US2020/042183 International Search Report and Written Opinion dated Oct. 27, 2020. [cited by applicant]
PCT/US2020/057996 International Search Report and Written Opinion dated Feb. 23, 2021. [cited by applicant]
U.S. Appl. No. 16/760,380 Office Action dated Jul. 12, 2021. [cited by applicant]
U.S. Appl. No. 17/078,567 Office Action dated Sep. 14, 2021. [cited by applicant]
U.S. Appl. No. 17/083,871 Office Action dated May 24, 2022. [cited by applicant]
U.S. Appl. No. 17/114,993 Office Action dated Jan. 27, 2021. [cited by applicant]
U.S. Appl. No. 17/697,318 Office Action dated Feb. 23, 2023. [cited by applicant]
U.S. Appl. No. 17/722,513 Office Action dated Nov. 16, 2023. [cited by applicant]
U.S. Appl. No. 18/051,125 Office Action dated Aug. 23, 2023. [cited by applicant]
Xin, et al. Solvate Prediction for Pharmaceutical Organic Molecules With Machine Learning. Crystal Growth & Design 19:1903-1911 (2019). [cited by applicant]
Zavorotinskaya et al. Poster #1023. CD73 Inhibition with a Novel Orally Bioavailable Small Molecule Blocks Adenosine Production and Rescues T-cell Activation. AACR Virtual Annual Meeting II, Jun. 22-24, 2020. [cited by applicant]
Zhang. CD73: A Novel Target for Cancer Immunotherapy. Cancer Research 70(16):6407-6411 (2010). [cited by applicant]
Hammouda, Mohamed M. et al. Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo [1, 5-a] pyrimidine scaffold. RSC Medicinal Chemistry 13(10):1150-1196 (2022). [cited by applicant]
Ott, Gregory R., and David A. Favor. Pyrrolo [2, 1-f][1, 2, 4] triazines: from C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycle. Bioorganic & Medicinal Chemistry Letter… [cited by applicant]
Stambasky, Jan et al. C-nucleosides: synthetic strategies and biological applications. Chemical Reviews 109(12):6729-6764 (2009). [cited by applicant]
U.S. Appl. No. 17/626,731 Office Action dated Mar. 19, 2025. [cited by applicant]
U.S. Appl. No. 18/476,763 Office Action dated Mar. 12, 2025. [cited by applicant]